CO2018002516A2 - Derivados de n-(4-cloro-3(hidroxi-1,3,5-triazin-2-il)bencil)-carboxamida, activos como inhibidores de prostaglandina microsomal e2 sintasa-1 (mpegs-1), composiciones de los mismos y métodos de preparación de los mismos - Google Patents
Derivados de n-(4-cloro-3(hidroxi-1,3,5-triazin-2-il)bencil)-carboxamida, activos como inhibidores de prostaglandina microsomal e2 sintasa-1 (mpegs-1), composiciones de los mismos y métodos de preparación de los mismosInfo
- Publication number
- CO2018002516A2 CO2018002516A2 CONC2018/0002516A CO2018002516A CO2018002516A2 CO 2018002516 A2 CO2018002516 A2 CO 2018002516A2 CO 2018002516 A CO2018002516 A CO 2018002516A CO 2018002516 A2 CO2018002516 A2 CO 2018002516A2
- Authority
- CO
- Colombia
- Prior art keywords
- mpegs
- triazin
- synthase
- chloro
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona un compuesto que tiene una actividad inhibidora de mPGES–1 y es de utilidad para la prevención o el tratamiento de dolor, reumatismo, osteoartritis, fiebre, enfermedad de Alzheimer, esclerosis múltiple, arteriosclerosis, glaucoma, hipertensión ocular, enfermedad retinal isquémica, esclerodermia sistémica y/o cáncer incluyendo cáncer colorrectal. La presente invención se refiere a un compuesto de la fórmula [I–a], [I–b] o [I–c] o una de sus sales farmacéuticamente aceptables: en donde cada símbolo es como se define en la memoria descriptiva.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015160284 | 2015-08-17 | ||
| PCT/JP2016/073879 WO2017030115A1 (ja) | 2015-08-17 | 2016-08-16 | ヒドロキシトリアジン化合物及びその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018002516A2 true CO2018002516A2 (es) | 2018-05-31 |
Family
ID=58052084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0002516A CO2018002516A2 (es) | 2015-08-17 | 2018-03-12 | Derivados de n-(4-cloro-3(hidroxi-1,3,5-triazin-2-il)bencil)-carboxamida, activos como inhibidores de prostaglandina microsomal e2 sintasa-1 (mpegs-1), composiciones de los mismos y métodos de preparación de los mismos |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20170057943A1 (es) |
| EP (2) | EP3339296A4 (es) |
| JP (4) | JP2017039714A (es) |
| KR (1) | KR20180037270A (es) |
| CN (1) | CN108137515B (es) |
| AR (1) | AR105711A1 (es) |
| AU (1) | AU2016309337B2 (es) |
| BR (1) | BR112018001809A2 (es) |
| CA (1) | CA2992410A1 (es) |
| CL (1) | CL2018000430A1 (es) |
| CO (1) | CO2018002516A2 (es) |
| IL (1) | IL257559B (es) |
| MX (1) | MX2018002044A (es) |
| PE (1) | PE20180951A1 (es) |
| PH (1) | PH12018500181A1 (es) |
| SG (1) | SG11201800698VA (es) |
| TW (1) | TWI704139B (es) |
| WO (1) | WO2017030115A1 (es) |
| ZA (1) | ZA201801134B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3372589T3 (da) * | 2015-10-29 | 2021-12-06 | Aska Pharm Co Ltd | Pyrimidinderivat |
| RU2648181C1 (ru) * | 2017-05-25 | 2018-03-22 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ лечения нейроретинопатии вследствие тяжелой преэклампсии |
| WO2019002183A1 (de) * | 2017-06-26 | 2019-01-03 | Merck Patent Gmbh | Verfahren zur herstellung substituierter stickstoffhaltiger heterocyclen |
| WO2024010015A1 (ja) * | 2022-07-06 | 2024-01-11 | あすか製薬株式会社 | ピリミジン誘導体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2138488A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
| GB2463788B (en) * | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| CN101747282A (zh) * | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
| US8952150B2 (en) * | 2009-09-23 | 2015-02-10 | Albert Einstein College Of Medicine Of Yeshiva University | Prostaglandin transporter inhibitors and uses thereof |
| AR086254A1 (es) * | 2011-05-26 | 2013-11-27 | Lilly Co Eli | Derivados de imidazol utiles para el tratamiento de artritis |
| TWI568722B (zh) * | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| WO2015059618A1 (en) * | 2013-10-22 | 2015-04-30 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS |
| TWI651310B (zh) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
-
2016
- 2016-08-16 SG SG11201800698VA patent/SG11201800698VA/en unknown
- 2016-08-16 EP EP16837104.5A patent/EP3339296A4/en not_active Withdrawn
- 2016-08-16 WO PCT/JP2016/073879 patent/WO2017030115A1/ja active Application Filing
- 2016-08-16 BR BR112018001809-0A patent/BR112018001809A2/pt not_active Application Discontinuation
- 2016-08-16 CN CN201680060597.6A patent/CN108137515B/zh active Active
- 2016-08-16 AU AU2016309337A patent/AU2016309337B2/en active Active
- 2016-08-16 KR KR1020187007349A patent/KR20180037270A/ko not_active Application Discontinuation
- 2016-08-16 EP EP22162814.2A patent/EP4046991A1/en active Pending
- 2016-08-16 TW TW105126071A patent/TWI704139B/zh active
- 2016-08-16 AR ARP160102503A patent/AR105711A1/es unknown
- 2016-08-16 US US15/237,763 patent/US20170057943A1/en not_active Abandoned
- 2016-08-16 MX MX2018002044A patent/MX2018002044A/es active IP Right Grant
- 2016-08-16 PE PE2018000185A patent/PE20180951A1/es unknown
- 2016-08-16 JP JP2016159454A patent/JP2017039714A/ja not_active Ceased
- 2016-08-16 CA CA2992410A patent/CA2992410A1/en active Pending
-
2018
- 2018-01-24 PH PH12018500181A patent/PH12018500181A1/en unknown
- 2018-02-15 IL IL257559A patent/IL257559B/en unknown
- 2018-02-16 CL CL2018000430A patent/CL2018000430A1/es unknown
- 2018-02-19 ZA ZA2018/01134A patent/ZA201801134B/en unknown
- 2018-03-12 CO CONC2018/0002516A patent/CO2018002516A2/es unknown
-
2020
- 2020-03-03 US US16/807,719 patent/US20210024486A1/en not_active Abandoned
- 2020-09-04 JP JP2020148973A patent/JP2020193235A/ja not_active Ceased
-
2022
- 2022-08-12 JP JP2022128590A patent/JP2022163169A/ja active Pending
-
2023
- 2023-02-24 US US18/114,043 patent/US20240076278A1/en active Pending
- 2023-12-08 JP JP2023207429A patent/JP2024019449A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018109220A (ru) | 2019-09-19 |
| AU2016309337B2 (en) | 2021-03-04 |
| CN108137515A (zh) | 2018-06-08 |
| IL257559B (en) | 2021-07-29 |
| ZA201801134B (en) | 2019-07-31 |
| TWI704139B (zh) | 2020-09-11 |
| AR105711A1 (es) | 2017-11-01 |
| EP3339296A1 (en) | 2018-06-27 |
| KR20180037270A (ko) | 2018-04-11 |
| EP4046991A1 (en) | 2022-08-24 |
| JP2017039714A (ja) | 2017-02-23 |
| MX2018002044A (es) | 2018-04-13 |
| EP3339296A4 (en) | 2019-01-23 |
| US20240076278A1 (en) | 2024-03-07 |
| AU2016309337A1 (en) | 2018-02-01 |
| SG11201800698VA (en) | 2018-03-28 |
| IL257559A (en) | 2018-04-30 |
| CA2992410A1 (en) | 2017-02-23 |
| PE20180951A1 (es) | 2018-06-11 |
| JP2024019449A (ja) | 2024-02-09 |
| BR112018001809A2 (pt) | 2018-09-18 |
| RU2018109220A3 (es) | 2019-11-15 |
| US20210024486A1 (en) | 2021-01-28 |
| TW201718524A (zh) | 2017-06-01 |
| US20170057943A1 (en) | 2017-03-02 |
| JP2022163169A (ja) | 2022-10-25 |
| WO2017030115A1 (ja) | 2017-02-23 |
| JP2020193235A (ja) | 2020-12-03 |
| CN108137515B (zh) | 2021-07-06 |
| CL2018000430A1 (es) | 2018-08-03 |
| PH12018500181A1 (en) | 2018-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017004481A2 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| PE20211548A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| CO2018002516A2 (es) | Derivados de n-(4-cloro-3(hidroxi-1,3,5-triazin-2-il)bencil)-carboxamida, activos como inhibidores de prostaglandina microsomal e2 sintasa-1 (mpegs-1), composiciones de los mismos y métodos de preparación de los mismos | |
| CL2017001050A1 (es) | Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| EA201890594A1 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| MX2023001876A (es) | Derivados de rapamicina. | |
| CL2020002562A1 (es) | (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| BR112019025049A2 (pt) | Anéis 6- 5 fundidos como inibidores de c5a | |
| EA202091016A1 (ru) | Пиримидиновое соединение в качестве ингибитора jak киназы | |
| AR096846A1 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
| PH12017500095A1 (en) | Imidazopyridazine compounds | |
| CY1123494T1 (el) | Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2 | |
| CY1121650T1 (el) | Αναστολεις συνθασης αλδοστερονης | |
| CO2019010559A2 (es) | Composiciones y compuestos terapéuticos y métodos para utilizarlos | |
| EA201692300A1 (ru) | Производные карбоксамида | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| TN2017000485A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| BR112021026682A2 (pt) | Compostos e métodos para inibir eif4e | |
| DOP2020000088A (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk2. | |
| EA201890616A1 (ru) | Сульфонамидные соединения в качестве модуляторов потенциалуправляемых натриевых каналов | |
| EA201991008A1 (ru) | Новые производные нафтиридинона и их применение в лечении аритмии | |
| AR105921A1 (es) | Compuestos terapéuticos para el dolor y síntesis de estos | |
| EA201790231A1 (ru) | Профилактическое или терапевтическое средство для лечения болезней заднего сегмента глаза |